Novel Theranostic and Nanotheranostic Agents for Targeted Radionuclide Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 432

Special Issue Editors


E-Mail Website
Guest Editor
1. Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil
2. Laboratory of Nanoradiopharmacy, Rio de Janeiro State University, Rio de Janeiro 23070-200, Brazil
Interests: radiopharmacy; radiopharmaceuticals; nano-radiopharmaceuticals; nanotechnology; nanoparticles and theranostics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Center for Radiopharmceutical Sciences, Paul Scherrer Institute, 5232 Villigen, Switzerland
Interests: radionuclide therapy; non-standard radionuclides; radiotheranostics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Targeted radionuclide therapy, including alpha- and beta- particle emitting radionuclides have revolutionized the concepts and application of radiopharmaceuticals in the field of nuclear oncology. Recently, the use of new radionuclides based on nanotechnology for therapy have increased the efficacy and augmented the advantages of such modality.

The aim of this special issue is to collect innovative, unpublished and high-quality research studies and reviews in the field of theranostic and nanotheranostic targeted radionuclide therapy. Thus, the special issue is dedicated to the following topics: theranostic; alpha and beta radionuclide therapy; effects of alpha or beta radiation in biological systems; production of emerging radionuclides for therapeutic purposes; pre-clinical and clinical investigations regarding radionuclide therapy; nanotechnology applied in radionuclide therapy; using nanotechnology to overcome barriers for radionuclide therapy; new nanotheranostic and reviews on all of these topics.

Dr. Ralph Santos-Oliveira
Dr. Cristina Müller
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • alpha therapy
  • beta therapy
  • radionuclide therapy
  • radionuclides
  • pre-clinical trials
  • clinical trials
  • nanotechnology
  • theranostic
  • nanotheranostic

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop